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Sir,
We thank Schaffer et al for the interest in our article. They have
highlighted relevant points for discussion from our study.
The conclusion of our study was that there was no statistical
difference in survival between the two arms comparing surgery
with postoperative radiotherapy (RT) as adjuvant and concurrent
chemoradiotherapy with surgical salvage. It was a very difficult
trial to undertake but an important one because up until then,
there has not been such a study. For many oncologists, surgery
with adjuvant radiotherapy is the standard practice for advanced
resectable head and neck cancers.
The reason we chose 66Gy instead of 70Gy was the reported
toxicity with concurrent chemoradiotherapy. It was described as
‘formidable’ (Adelstein et al, 1997). There were other significant
institutions that used 66Gy for definitive radiation for stage III and
IV head and neck cancers (Grau et al, 2003), more so when
chemotherapy was given concurrently. In the Adelstein/Intergroup
trial (Adelstein et al, 2003) quoted, the RT dose of 70Gy was given
continuously only for the arm that received single agent
concurrent Cisplatin. The arm that received Cisplatin and 5FU
had a split course RT regimen. A better comparison would be
Adelstein’s previous Phase III trial (Adelstein et al, 1997) that
treated patients to 68–72Gy at 1.8–2Gy fractions (even in patients
with RT alone), and Cisplatin and 5FU was given on days 1 and 22
of radiotherapy. Currently, 66Gy is still an acceptable standard
(Dobbs et al, 1985, 1992, 1999) for radical RT for head and neck
cancers. Whether there will be any relevant clinical difference
between 66, 68 or 70Gy is debatable – certainly in cancers of the
oeosophagus, a randomized trial (Minsky et al, 2002) has failed to
show any difference between 50.4 and 64.8Gy, when Cisplatin and
5FU was given concurrently with RT. The concern in our protocol
was obviously normal tissue toxicity, especially when we were
adding two drugs concurrent with the RT regimen. Rather than the
higher toxicity being contributed by treatment interruptions, it
was precisely because of higher toxicity that there were treatment
interruptions.
The low accrual rate was not because patients preferred surgery.
In our context, the majority of patients preferred the nonsurgical
arm and that was an important contributing factor to the low
accrual.
All patients were initially assessed by the head and neck surgeon
for resectability. They were then presented at a multidisciplinary
tumour board, where there were in addition to radiation and
medical oncologists, other surgical oncologists who provided
another assessment of resectabilility.
We did not have second thoughts about whether every
resectable tumour is preferably treated by surgery rather than
chemoradiotherapy. We were reporting what we observed at the
end of the study.
As to the question, which T4 tumours should be operated, it will
be difficult to generalize. What we can say is that there is no
difference in survival with either therapy and other considerations
will need to play a role in the decision making. While we agree that
in a significant number of patients with laryngeal cancer, the
disease can be managed without surgery, it cannot be for all. The
EOTRC (Bernier et al, 2004) and the RTOG (Cooper et al, 2004)
postoperative trials had significant number of patients with
laryngeal cancers. There are, notwithstanding the VA study of
1991 (The Department of Veterans Affairs Laryngeal Cancer Study
Group, 1991), considerable number of oncologists who can
ethically and with a clear conscience refer patients for definitive
surgical treatment of advanced laryngeal cancers.
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